JPWO2019031614A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019031614A5 JPWO2019031614A5 JP2019535732A JP2019535732A JPWO2019031614A5 JP WO2019031614 A5 JPWO2019031614 A5 JP WO2019031614A5 JP 2019535732 A JP2019535732 A JP 2019535732A JP 2019535732 A JP2019535732 A JP 2019535732A JP WO2019031614 A5 JPWO2019031614 A5 JP WO2019031614A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- cancer
- group
- antibody
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 38
- 239000000611 antibody drug conjugate Substances 0.000 claims 33
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 33
- 230000001093 anti-cancer Effects 0.000 claims 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 21
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 16
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000029742 colonic neoplasm Diseases 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 229940043355 kinase inhibitor Drugs 0.000 claims 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 4
- 125000005907 alkyl ester group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 3
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 3
- 229940100198 alkylating agent Drugs 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 3
- 230000008512 biological response Effects 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 230000001973 epigenetic effect Effects 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 229940125697 hormonal agent Drugs 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 229950008085 figitumumab Drugs 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229950010012 nemolizumab Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 229950007217 tremelimumab Drugs 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229950009106 altumomab Drugs 0.000 claims 1
- 229950010117 anifrolumab Drugs 0.000 claims 1
- 229950005794 anrukinzumab Drugs 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 229950003145 apolizumab Drugs 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 229950009658 cofetuzumab Drugs 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 229950008962 detumomab Drugs 0.000 claims 1
- 229960004497 dinutuximab Drugs 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 229940096918 enapotamab Drugs 0.000 claims 1
- 229950004912 etrolizumab Drugs 0.000 claims 1
- 229950000335 fasinumab Drugs 0.000 claims 1
- 229950010512 fezakinumab Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229950001813 laprituximab Drugs 0.000 claims 1
- 229950007708 namilumab Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229950008836 tosatoxumab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229950010086 tregalizumab Drugs 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022199206A JP7235929B1 (ja) | 2017-08-10 | 2022-12-14 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017155990 | 2017-08-10 | ||
| JP2017155990 | 2017-08-10 | ||
| PCT/JP2018/030143 WO2019031614A1 (ja) | 2017-08-10 | 2018-08-10 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199206A Division JP7235929B1 (ja) | 2017-08-10 | 2022-12-14 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2019031614A1 JPWO2019031614A1 (ja) | 2020-07-16 |
| JPWO2019031614A5 true JPWO2019031614A5 (https=) | 2022-05-23 |
Family
ID=65272282
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535732A Withdrawn JPWO2019031614A1 (ja) | 2017-08-10 | 2018-08-10 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
| JP2022199206A Active JP7235929B1 (ja) | 2017-08-10 | 2022-12-14 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
| JP2023027362A Active JP7623413B2 (ja) | 2017-08-10 | 2023-02-24 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
| JP2024179365A Withdrawn JP2025004232A (ja) | 2017-08-10 | 2024-10-11 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199206A Active JP7235929B1 (ja) | 2017-08-10 | 2022-12-14 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
| JP2023027362A Active JP7623413B2 (ja) | 2017-08-10 | 2023-02-24 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
| JP2024179365A Withdrawn JP2025004232A (ja) | 2017-08-10 | 2024-10-11 | ヘミアスタリン誘導体を含む抗体薬物複合体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11795195B2 (https=) |
| EP (1) | EP3666787B9 (https=) |
| JP (4) | JPWO2019031614A1 (https=) |
| CN (1) | CN111032676B (https=) |
| CA (1) | CA3072153A1 (https=) |
| DK (1) | DK3666787T3 (https=) |
| ES (1) | ES2974288T3 (https=) |
| FI (1) | FI3666787T3 (https=) |
| HU (1) | HUE066314T2 (https=) |
| PL (1) | PL3666787T3 (https=) |
| PT (1) | PT3666787T (https=) |
| TW (1) | TWI805602B (https=) |
| WO (1) | WO2019031614A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4321523A3 (en) * | 2017-08-10 | 2024-04-24 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivatives and antibody-drug conjugates including same |
| WO2020166592A1 (ja) * | 2019-02-13 | 2020-08-20 | 大日本住友製薬株式会社 | ヘミアスタリン誘導体とその抗体薬物複合体 |
| JP7432531B2 (ja) * | 2019-02-13 | 2024-02-16 | 住友ファーマ株式会社 | システイン残基を有するヘミアスタリン誘導体 |
| JP7437328B2 (ja) * | 2019-02-13 | 2024-02-22 | 住友ファーマ株式会社 | 多能性幹細胞の除去剤 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508195D0 (en) * | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
| CA2225325A1 (en) | 1997-12-19 | 1999-06-19 | The University Of British Columbia | Hemiasterlin analogs |
| US6154590A (en) | 1998-09-28 | 2000-11-28 | Lucent Technologies Inc. | Wavelength-tunable devices and systems comprising flexed optical gratings |
| EP1531846A4 (en) * | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| KR101208266B1 (ko) | 2002-03-22 | 2012-12-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤미아스텔린 유도체 및 이의 용도 |
| WO2004026293A2 (en) | 2002-09-20 | 2004-04-01 | Wyeth Holdings Corporation | Hemiasterlin derivatives for treating resistant tumors |
| JP2008522624A (ja) | 2004-12-09 | 2008-07-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング |
| JP4945448B2 (ja) * | 2005-08-22 | 2012-06-06 | 株式会社クレハ | アミン誘導体、その製造方法及び用途 |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| RU2583270C2 (ru) * | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2014057436A2 (en) * | 2012-10-10 | 2014-04-17 | Adamed Sp. Z O.O. | Anticancer conjugate |
| HK1220626A1 (zh) * | 2013-03-15 | 2017-05-12 | The Centre For Drug Research And Development | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
| BR112016015105A8 (pt) | 2013-12-27 | 2018-04-24 | Var2 Pharmaceuticals Aps | conjugados var2csa-droga |
| WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
| GB201402009D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| PT3250237T (pt) * | 2015-01-30 | 2021-06-30 | Sutro Biopharma Inc | Derivados de hemiasterlina para conjugação e terapêutica |
| WO2015151079A2 (en) * | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
-
2018
- 2018-08-10 PL PL18843388.2T patent/PL3666787T3/pl unknown
- 2018-08-10 US US16/637,099 patent/US11795195B2/en active Active
- 2018-08-10 FI FIEP18843388.2T patent/FI3666787T3/fi active
- 2018-08-10 PT PT188433882T patent/PT3666787T/pt unknown
- 2018-08-10 WO PCT/JP2018/030143 patent/WO2019031614A1/ja not_active Ceased
- 2018-08-10 HU HUE18843388A patent/HUE066314T2/hu unknown
- 2018-08-10 JP JP2019535732A patent/JPWO2019031614A1/ja not_active Withdrawn
- 2018-08-10 CA CA3072153A patent/CA3072153A1/en active Pending
- 2018-08-10 DK DK18843388.2T patent/DK3666787T3/da active
- 2018-08-10 CN CN201880051277.3A patent/CN111032676B/zh active Active
- 2018-08-10 TW TW107128094A patent/TWI805602B/zh active
- 2018-08-10 ES ES18843388T patent/ES2974288T3/es active Active
- 2018-08-10 EP EP18843388.2A patent/EP3666787B9/en active Active
-
2022
- 2022-12-14 JP JP2022199206A patent/JP7235929B1/ja active Active
-
2023
- 2023-02-24 JP JP2023027362A patent/JP7623413B2/ja active Active
- 2023-07-03 US US18/217,962 patent/US20240059732A1/en active Pending
-
2024
- 2024-10-11 JP JP2024179365A patent/JP2025004232A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019031614A5 (https=) | ||
| JP7028996B2 (ja) | 核輸送モジュレーターとしての化合物およびその使用 | |
| JP2022511351A5 (https=) | ||
| JP2021510696A5 (https=) | ||
| JP2020514321A5 (https=) | ||
| JP2024520283A (ja) | 化学的カップリングリンカー及びその使用 | |
| JP2020506951A5 (https=) | ||
| TW202203978A (zh) | 電荷可變連接子 | |
| US20210139596A1 (en) | Modified antibodies and related compounds, compositions and methods of use | |
| CA3134420A1 (en) | Methods for modulating macrophage activity | |
| JP2022549510A5 (https=) | ||
| TW202246242A (zh) | 免疫調節抗體藥物結合物 | |
| RU2012144844A (ru) | Комплексные соединения железа(iii) для лечения и профилактики симптомов железодефицита и железодефицитной анемии | |
| JP7519347B2 (ja) | キノリン誘導体を含む薬物複合体 | |
| JP2005537245A5 (ja) | プロテイナーゼ活性化レセプターのアンタゴニストを含む組成物および方法 | |
| JP2021525765A5 (https=) | ||
| CN112367996A (zh) | 使用剪接调节剂的方法 | |
| JPWO2020040245A5 (https=) | ||
| JP2022537019A5 (https=) | ||
| Helguera et al. | Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors | |
| WO2021206160A1 (ja) | 抗体薬物複合体 | |
| JP2020132638A5 (https=) | ||
| JPWO2020166592A5 (https=) | ||
| CN111032676A (zh) | 包含哈米特林衍生物的抗体药物复合物 | |
| JP2025507736A (ja) | 投薬レジメン |